Sparks - Sareum Holdings

Sareum has announced plans to undertake an equity fundraise to support the continued development of its lead asset, SDC-1801, an oral TYK2/JAK1 inhibitor. The company has opted to use AIM’s recently introduced Capital Access Window, which allows for temporarily suspension of share trading to facilitate a more orderly fundraising process, provide greater pricing stability and potentially broaden investor participation. The proposed fundraising size, pricing and other terms have yet to be disclosed.

We view the initiative as a timely step towards strengthening Sareum’s financial position ahead of important upcoming milestones. With dosing in SDC-1801’s toxicology study completed and Phase II-enabling regulatory package targeted for completion by Q426, additional funding could support continued development momentum. The financing requirement was largely anticipated, and we had previously noted a runway into Q4 CY26, with Sareum last reporting cash of £2.5m at end-December 2025. A successful raise could provide greater operational flexibility, alleviate near-term funding uncertainty and strengthen Sareum’s negotiating position in potential licensing discussions.